Epic Code LAB1230508 Diphtheria/Tetanus Antibody Panel, Serum
Additional Codes
Mayo Code: DTABS
Interface Code: 1230508
Performing Laboratory

Useful For
Assessment of an antibody response to tetanus and diphtheria toxoid vaccines, which should be performed at least 3 weeks after immunization
Aiding in the evaluation of immunodeficiency
This test should not be used to diagnose tetanus infection
Specimen Type
SerumSpecimen Required
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 1 mL
COLLECTION NOTE: Volumes listed are in serum or plasma, draw approximately 2 1/2 times the requested volume in whole blood.
Specimen Minimum Volume
0.8 mL
Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 30 days | |
Frozen | 30 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat Inactivated specimen | Reject |
Cautions
This assay does not provide diagnostic proof of lack of protection again diphtheria or the presence of absence of immunodeficiency. Results must be confirmed by clinical findings and other serological tests.
The diagnosis of tetanus is by clinical observation. A positive wound culture for the agent of tetanus, Clostridium tetani, may support, but does not confirm, the diagnosis. Toxin assays for tetanospasmin may be useful but are only available in a few laboratories.
The results obtained from this assay are not diagnostic proof of lack of protection against tetanus or the presence or absence of immunodeficiency.
Clinical Information
Diphtheria is an acute, contagious, febrile illness caused by the bacterium Corynebacterium diphtheriae. The disease is classically characterized by a combination of localized inflammation in the upper respiratory tract with the formation of a diphtheric pseudomembrane over the oropharynx, including the tonsils, pharynx, larynx, and posterior nasal passages. C diphtheriae produces a potent diphtheria exotoxin that is absorbed systemically and can lead to cardiac failure and paralysis of the diaphragm.
The disease is preventable by vaccination with diphtheria toxoid, which stimulates antidiphtheria toxoid antibodies. In the United States, diphtheria toxoid is administered to children as part of the combined diphtheria, tetanus, acellular pertussis (TDaP) vaccine. A patient's immunological response to diphtheria toxoid vaccination can be determined by measuring antidiphtheria toxoid IgG antibody using this enzyme immunoassay technique. An absence of antibody formation postvaccination may relate to immune deficiency disorders, either congenital or acquired, or iatrogenic due to immunosuppressive drugs.
Tetanus results from contamination of wounds or lacerations with Clostridium tetani spores from the environment. The spores germinate to actively replicating bacterial cells localized within the wound and produce the heat-labile toxin, tetanospasmin. Tetanospasmin attaches to peripheral nerve endings and travels to the central nervous system (CNS) where it blocks inhibitory impulses to motor neurons and leads to severe, spastic muscle contractions, a classic characteristic of tetanus.
The disease is preventable by vaccination with tetanus toxoid (formaldehyde-treated tetanospasmin), which stimulates development of antitetanus toxoid antibodies. In the United States, tetanus toxoid is administered to children as part of the combined diphtheria, tetanus, acellular pertussis (TDaP) vaccine.
Two to 3 weeks following vaccination, a patient's immunological response may be assessed by measuring the total antitetanus toxoid IgG antibody level in serum. An absence of antibody formation postvaccination may relate to immune deficiency disorders, either congenital or acquired, or iatrogenic due to immunosuppressive drugs.
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Report Available
Same day/1 to 4 daysReporting Name
Diphtheria/Tetanus Ab Panel, SReference Values
DIPHTHERIA TOXOID IgG ANTIBODY
Vaccinated: Positive (≥0.01 IU/mL)
Unvaccinated: Negative (<0.01 IU/mL)
Reference values apply to all ages.
TETANUS TOXOID IgG ANTIBODY
Vaccinated: Positive (≥0.01 IU/mL)
Unvaccinated: Negative (<0.01 IU/mL)
Reference values apply to all ages.
Interpretation
Diphtheria:
Results of 0.01 IU/mL or more suggest a vaccine response.
A diphtheria toxoid booster should be considered for patients with antidiphtheria toxoid IgG values between 0.01 and less than 0.1 IU/mL
Tetanus:
Results of 0.01 IU/mL or more suggest a vaccine response.
A tetanus toxoid booster should strongly be considered for patients with antitetanus toxoid IgG values between 0.01 and 0.5 IU/mL.
Some cases of tetanus, usually mild, have occasionally been observed in patients who have a measurable serum level of 0.01 to 1.0 IU/mL.
Method Description
The EuroImmun Anti-Diphtheria Toxoid enzyme-linked immunosorbent assay (ELISA)and Anti-Tetanus Toxoid ELISA provide quantitative in-vitro assays for detection of human IgG-class antibodies to diphtheria and tetanus toxoid, respectively.
The test kits contain reagent wells coated with either diphtheria or tetanus toxoid. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled antihuman IgG (enzyme conjugate) catalyzing a color reaction.(Package inserts: Anti-Tetanus Toxoid ELISA [IgG] Test instruction. 08/28/2017; Anti-Diphtheria Toxoid ELISA [IgG] Test instruction. EUROIMMUN US;08/18/2017)
Day(s) Performed
Monday through Friday
Clinical Reference
1. Booy R, Aitken SJ, Taylor S, et al: Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet. 1992;339(8792):507-510
2. Maple PA, Efstratiou A, George RC, Andrews NJ, Sesardic D: Diphtheria immunity in UK blood donors. Lancet. 1995;345(8955):963-965
3. Bleck TP: Clostridium tetani (tetanus). In: Mandell GL, Bennett JE, Dolin R, eds. Principals and Practice of Infectious Disease. 5th ed. Churchill Livingstone;2000:2537-2543
4. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G: A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332:761-766
5. Bjorkholm B, Wahl M, Granstrom M, Hagberg L: Immune status and booster effects of low doses of tetanus toxoid in Swedish medical personnel. Scand J Infect Dis. 1994;26:471-475
6. Ramsay ME, Corbel MJ, Redhead K, Ashworth LA, Begg NT: Persistence of antibody after accelerated immunization with diptheria/tetanus/pertussis vaccine. Br Med J. 1991;302:1489-1491
7. Wagner KS, White JM, Lucenko I, et al: Diphtheria in the postepidemic period, Europe, 2000-2009. Emerg Infect Dis. 2012 Feb;18(2):217-225 doi: 10.3201/eid1802.110987
Test Classification
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86317 x 2
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DTABS | Diphtheria/Tetanus Ab Panel, S | In Process |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
TETG | Tetanus IgG Ab | 33469-8 |
DIPG | Diphtheria IgG Ab | 45166-6 |
DEXDP | Diphtheria IgG Value | 48654-8 |
DEXTG | Tetanus IgG Value | 53935-3 |
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
DIPGS | Diphtheria Toxoid IgG Ab, S | Yes | Yes |
TTIGS | Tetanus Toxoid IgG Ab, S | Yes | Yes |